Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine

NCT ID: NCT00846495

Last Updated: 2012-01-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 55 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-08-31
• Study Completion Date: 2011-01-31

Brief Summary

Subjects enrolled at 2 investigative sites will complete 3 visits. Following Visit 1, during a 1-month Baseline Period, subjects will treat with their usual medication and document any warning signs (Prodrome pre-headache) that a migraine will occur. Following randomization (like a flip of the coin) at Visit 2, subjects will treat daily with topiramate or during Prodrome with frovatriptan. Subjects complete a 2-month Treatment Period before exit at Visit 3.This study will compare the effectiveness of daily treatment vs. treatment during the pre-headache phase for prevention of migraine.

Conditions

Migraine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

topiramate

Subjects randomized to Group A at Visit 2 were provided with topiramate, titrated over 4 weeks to a maximum dose of 100 mg daily. One dosage adjustment was allowed with a minimum dose of 50 mg daily.

Group Type: ACTIVE_COMPARATOR

topiramate

Intervention Type: DRUG

topiramate 25mg 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 2 tabs in PM x 1 week topiramate 25mg 2 tabs in AM / 2 tabs in PM x 5 weeks

frovatriptan

Subjects randomized to Group B at Visit 2 were provided with frovatriptan 5 mg to treat during prodrome at the point they were confident a disabling migraine would occur (before the onset of headache).

Group Type: ACTIVE_COMPARATOR

frovatriptan

Intervention Type: DRUG

frovatriptan 5mg tab during premonitory phase of migraine

Interventions

topiramate

topiramate 25mg 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 2 tabs in PM x 1 week topiramate 25mg 2 tabs in AM / 2 tabs in PM x 5 weeks

Intervention Type: DRUG

frovatriptan

frovatriptan 5mg tab during premonitory phase of migraine

Intervention Type: DRUG

Other Intervention Names

Topamax; Frova

Eligibility Criteria

Inclusion Criteria

1. Subject has at least a one-year history of migraine with or without aura meeting International Headache Society criteria (see Appendix)

2. Subject has a 3-month history of averaging 3-6 migraines per month

3. Subject reports premonitory symptoms and the ability to predict at least 50% of high impact headaches

4. Subjects must currently or have in the past successfully utilized a triptan as an acute treatment for migraine as determined by the investigator.

5. Male or female at least 18 years of age

6. Subject of childbearing potential agrees to use adequate contraception during the study. Adequate methods of contraception are to be determined by the investigator and should be consistent with contraceptive care administered in the regular clinical use of frovatriptan and topiramate.

7. Subject is aware of prodrome symptoms that may include physiological, psychological or cognitive changes. These may include, but are not limited to such symptoms as Pre-Menstrual Syndrome (PMS), change in mood, energy level, appetite, food craving, nausea, sense of hearing, sense of smell or swelling/fluid retention, excessive yawning, head pain, muscle pain/tenderness, irritability, confusion, extreme sleepiness, impaired speech or impaired memory. (The subject should be able to differentiate these symptoms from other similar symptoms that do not precede migraine). The symptoms should precede migraine by 4-24 hours signaling an impending migraine attack.

8. Subject is able to understand instructions for the study and complete the diary

9. Subject is willing to give informed consent to participate in the study

10. Any migraine prophylactic medication must have a stabilized dosage for one month

Exclusion Criteria

1. History of any medical condition that would confound the results of the study including but not limited to the following:

• Hepatic disease or significant hepatic dysfunction
• History of pancreatitis
• History of thrombocytopenia
• History of glaucoma
• History of osteoporosis or osteopenia
• Cardiovascular Disease - Coronary artery disease, Ischemic heart disease or Significant Arrhythmia
• History of active Cerebrovascular Disease
• Hypertension - Uncontrolled hypertension in a non-migrainous state (> 160 mmHg systolic or >95 mmHg. diastolic). Hypertension must be controlled effectively with medication for a period of 3 months.
• Basilar or Hemiplegic Migraine
• Significant peripheral vascular disease or Raynaud's Syndrome
• Significant Active Renal, Hepatic, Gastrointestinal, Endocrine or
• Neurological Disease
• History of depression, mood problems or suicidal thoughts or behavior that in the opinion of the Investigator would interfere with participation in the study.

2. History of ergotamine, "triptan", or analgesic abuse within past 3 months

3. History of current or recent drug or alcohol abuse that would interfere with participation in the study.

4. More than 15 headache days per month within past 3 months.

5. Women who are pregnant or breast feeding

6. Subjects with known hypersensitivity or intolerance to topiramate or any triptan-like medication

7. Subject is scheduled for surgical procedure to occur while enrolled in study.that in opinion of the Investigator would interfere with participation in the study.

8. Subject is on a ketogenic diet

9. Participation in another investigative drug study within the previous 30 days

10. Excluded medications: MAO Inhibitors, lithium, methylergonovine, methysergide, ergotamine-containing products, or topiramate daily for migraine prophylaxis.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Endo Pharmaceuticals

INDUSTRY

Sponsor Role: collaborator

Clinvest

INDIV

Sponsor Role: lead

Responsible Party

Clinvest

CEO

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Roger K Cady, MD

Role: PRINCIPAL_INVESTIGATOR

Clinvest

Locations

Physician Associates LLC

Oviedo, Florida, United States

Clinvest

Springfield, Missouri, United States

Countries

United States

References

Luciani R, Carter D, Mannix L, Hemphill M, Diamond M, Cady R. Prevention of migraine during prodrome with naratriptan. Cephalalgia. 2000 Mar;20(2):122-6. doi: 10.1046/j.1468-2982.2000.00030.x.

Reference Type: BACKGROUND

PMID: 10961768 (View on PubMed)

Other Identifiers

Frova vs. Topiramate

Identifier Type: -

Identifier Source: org_study_id